The LOTEMAX (loteprednol etabonate ophthalmic gel) gel is described as a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.
Loteprednol etabonate, the active ingredient in LOTEMAX gel, was first approved as an ocular anti-inflammatory agent by FDA in 1998.
Related Articles on Ophthalmology:
Ophthalmologist on the Move: Dr. Steven Brady Joins WA’s Cascade Eye & Skin Centers
Ophthalmologist Dr. Robert Massof Receives ‘Champion of Change’ Honor at White House
Global Ophthalmology Devices Market Projected to Reach $18B in 2018
